Abstract
Rheumatologists are focusing on both new and established drugs in attempts to improve the treatment of rheumatoid arthritis (RA). In particular, the selectivity of meloxicam for cyclo-oxygenase type 2 (COX-2), and a possible novel mechanism of action for sulfasalazine in reducing levels of cell adhesion molecules (CAMs), are attracting interest. Additionally, pulsed cyclophosphamide therapy is effective in systemic vasculitis, and intramuscular methylprednisolone may be an effective way of reducing corticosteroid dosages in polymyalgia rheumatica. These findings were presented at the 12th Annual General Meeting of the British Society for Rheumatology [Glasgow, UK; April, 1995].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
